Hypercoagulable Parameters as Predictors of Thrombotic Events and Prognosis in Patients With Advanced Non-Small Cell Lung Carcinoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Galit Sarig, Ph.D
- Phone Number: +972-4-8543503
- Email: g_sarig@rambam.health.gov.il
Study Contact Backup
- Name: Nissim Haim, M.D
Study Locations
-
-
-
Haifa, Israel
- Recruiting
- Hematology Laboratory
-
Contact:
- Galit Sarig, Ph.D
- Phone Number: +972-4-8543523
- Email: g_sarig@rambam.health.gov.il
-
Principal Investigator:
- Galit Sarig, Ph.D
-
Haifa, Israel
- Recruiting
- Oncology Institution, Rambam Health Campus
-
Contact:
- Nissim Haim, M.D
- Email: n_haim@rambam.health.gov.il
-
Principal Investigator:
- Nissim Haim, M.D
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically or cytologically confirmed diagnosis of NSCLC.
- normal serum bilirubin
- informed concent to participate in the study
Exclusion Criteria:
- anticoagulant therapy
- infectious disease
Study Plan
How is the study designed?
Design Details
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Galit Sarig, Ph.D, Rambam Health Care Campus
Publications and helpful links
General Publications
- Haim N, Lanir N, Hoffman R, Haim A, Tsalik M, Brenner B. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am J Med. 2001 Feb 1;110(2):91-6. doi: 10.1016/s0002-9343(00)00691-4.
- Blom JW, Osanto S, Rosendaal FR. The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost. 2004 Oct;2(10):1760-5. doi: 10.1111/j.1538-7836.2004.00928.x.
- Ferrigno D, Buccheri G, Ricca I. Prognostic significance of blood coagulation tests in lung cancer. Eur Respir J. 2001 Apr;17(4):667-73. doi: 10.1183/09031936.01.17406670.
Study record dates
Study Major Dates
Study Start
Study Start
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Hematologic Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Embolism and Thrombosis
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma
- Thromboembolism
- Venous Thromboembolism
- Thrombophilia
Other Study ID Numbers
Other Study ID Numbers
- Thrombosis and cancer.CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.